DeYuan Pharmaceuticals: The national drug regulatory authority issued the drug registration certificate for Rosuvastatin Ezetimibe tablets.

DeYuan Pharmaceutical Announcement, on March 13, 2026, the company received the drug registration certificate issued by the National Medical Products Administration for the drug Ruishufatatin Ezetimibe Tablets declared as a Class 4 chemical drug, and it is considered to have passed consistency evaluation. Ruishufatatin Ezetimibe Tablets is a lipid-lowering drug that contains two complementary mechanisms of action, Ruishufatatin and Ezetimibe. It can reduce levels of plasma total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and non-high-density lipoprotein cholesterol by inhibiting cholesterol absorption and synthesis, and can also increase high-density lipoprotein cholesterol levels.